QGEN · Qiagen N.V.
$50.39
+0.34% last session
End-of-day data · close of 2026-10-23
Market cap
$10B
Enterprise value
$11B
Trailing P/E
25.6
Forward P/E
19.3
Dividend yield
1.0%
Beta
0.61
Avg volume
3M
Employees
6K
Daily Change %
0.34%
5 Days Change
8.87%
10 Days Change
10.52%
30 Days Change
14.89%
60 Days Change
20.20%
Month to Day Change
19.46%
Year to Day Change
12.68%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — QGEN
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-10-22
Latest call per bank · past 12 months
JP Morgan
Neutral$52.00
+3.2% vs priceBarclays
Overweight$55.00
+9.1% vs priceUBS
Neutral$47.00
-6.7% vs priceCitigroup
Neutral$45.00
-10.7% vs priceMorgan Stanley
Overweight$42.00
-16.7% vs priceDeutsche Bank
Buy$54.00
+7.2% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-10-22 | JP Morgan | Downgrade | Overweight → Neutral | $55.00 → $52.00 |
| 2026-10-22 | Baird | Maintains | Outperform | $50.00 → $52.00 |
| 2026-10-14 | JP Morgan | Maintains | Overweight | $50.00 → $55.00 |
| 2026-10-06 | Barclays | Upgrade | Equal-Weight → Overweight | $40.00 → $55.00 |
| 2026-09-09 | UBS | Maintains | Neutral | $52.00 → $47.00 |
| 2026-08-10 | Citigroup | Maintains | Neutral | $38.00 → $45.00 |
| 2026-08-07 | Barclays | Maintains | Equal-Weight | $38.00 → $40.00 |
| 2026-08-07 | JP Morgan | Maintains | Overweight | $45.00 → $50.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-10-23
- bearish: RSI (14): RSI is 75 — overbought territory; the recent run-up may be due for a pause.
- bullish: Price vs 50-day MA: Trading 13.4% above the 50-day MA ($44.43).
- bullish: Price vs 200-day MA: Trading 19.1% above the 200-day MA ($42.30).
- bullish: MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- bullish: MACD (12,26,9): MACD histogram is positive (+0.52) — short-term momentum is improving.
- neutral: 52-week range: Price sits between the 52-week low ($32.34) and high ($55.16).
QGEN Price Chart
Loading chart for QGEN…
Fundamentals
About Qiagen N.V.
Qiagen N.V. provides sample to insight solutions that transform biological samples into molecular insights worldwide. The company offers sample technology consumables, such as nucleic acid stabilization and purification kits for sample materials, manual and automated processing for genotyping, gene expression, and viral and bacterial analysis, as well as silica membranes and magnetic bead technologies; secondary sample technology consumables, including kits and components for purification of nucleic acids; and instruments for nucleic acid purification, quality control, and accessories. It also provides Immune response consumables, such as interferon-gamma release assay for TB testing, and assays for post-transplant testing and viral load monitoring; oncology and sexual and reproductive health consumables, inclsuing assays for prenatal testing and detection of sexually transmitted diseases and HPV; assays for analysis of genomic variants; and sample to insight instruments, including one-step molecular analysis of hard-to-diagnose syndromes, and integrated PCR testing. The company offers research PCR consumables, such as quantitative PCR, reverse transcription, and combinations kits for analysis of gene expression, genotyping and gene regulation, and running on QIAGEN instruments and technologies; human ID/forensics assay consumables comprising short tandem repeat assays for human ID, and assays for food contamination; PCR instruments, including digital PCR and qPCR solutions; and developed and configured enzymes and PCR solutions. It offers NGS gene panels, library prep kits and components, and whole genome amplification; DNA methylation analysis; QIAGEN consumables and instruments; bioinformatics solutions; and sequence-based assays forensic genetic genealog services. it provides software-as-a-service. It serves molecular diagnostics and life sciences sectors. The company was founded in 1984 and is headquartered in Venlo, the Netherlands.
More in Diagnostics & Research
TMO
Thermo Fisher Scientific Inc
$249B 17.1% YTD
DHR
Danaher Corporation
$162B 1.0% YTD
NTRA
Natera, Inc.
$58B 75.2% YTD
A
Agilent Technologies, Inc.
$49B 28.7% YTD
IQV
IQVIA Holdings, Inc.
$46B 23.5% YTD
WAT
Waters Corporation
$45B 20.0% YTD
IDXX
IDEXX Laboratories, Inc.
$44B -16.2% YTD
ILMN
Illumina, Inc.
$41B 105.4% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.